How Metabolic Syndrome Rewires the Bladder: Animal Models Reveal Key Mechanisms

Lower urinary tract dysfunction, a cluster of conditions that includes overactive bladder, poor emptying and incontinence, has long been treated as a problem of aging alone. A comprehensive review published in Nature Reviews Urology now draws together the evidence from decades of preclinical research showing that metabolic syndrome, the dangerous combination of obesity, diabetes, dyslipidaemia and hypertension that affects hundreds of millions of people worldwide, is a major and mechanistically distinct driver of bladder dysfunction. The review, led by Lysanne Campeau and colleagues at the Lady Davis Institute and McGill University in Montreal, maps how each metabolic component damages the lower urinary tract through separate but overlapping biological pathways, and it critically evaluates the animal models scientists rely on to study these processes.

The clinical motivation is substantial. Epidemiological studies have linked metabolic syndrome to lower urinary tract symptoms in both men and women, to benign prostatic hyperplasia, and to overactive bladder, with the burden rising in parallel with the global obesity epidemic. Yet translating those associations into therapies requires mechanistic understanding, and that is precisely where animal models earn their keep. By isolating individual components of metabolic syndrome, researchers can dissect cause and effect in ways impossible in human cohorts, where obesity, insulin resistance and vascular disease almost always coexist.

The most extensively characterized models are those of diabetes. Streptozotocin-induced rodents, in which the insulin-producing beta cells are chemically destroyed, have revealed a striking biphasic progression of diabetic bladder dysfunction. In the early compensated phase, the detrusor muscle becomes hyperactive and hypertrophied, driven by polyuria and hyperglycaemia-induced oxidative stress. With time, the bladder decompensates: neural degeneration, fibrosis, apoptosis and falling levels of nerve growth factor in the bladder and lumbosacral dorsal root ganglia lead to an underactive, poorly contracting organ that empties incompletely. This transition from storage urgency to retention mirrors what clinicians observe in diabetic cystopathy, and studies antagonizing proneurotrophin signalling through the p75NTR receptor have even shown that the remodelling can be partially reversed.

Chemical models, however, do not capture the slow, polygenic nature of human type 2 diabetes. For that, researchers turn to strains such as the TallyHo mouse, the KK-Ay mouse, the Otsuka Long-Evans Tokushima Fatty rat and the Goto-Kakizaki rat, all of which develop spontaneous hyperglycaemia with varying degrees of obesity. Work in these polygenic models has confirmed the time-dependent shift from detrusor overactivity to underactivity and has highlighted the contribution of insulin resistance itself: insulin normally relaxes the bladder via a PI3K/AKT/eNOS pathway in the urothelium, and when that signalling becomes resistant, overactivity follows. Fructose-fed rats, which model dietary insulin resistance, have been particularly valuable here, and drugs such as tadalafil that restore mucosal insulin signalling have ameliorated bladder overactivity in these animals.

Obesity contributes to lower urinary tract symptoms through routes that go beyond diabetes. Leptin-deficient ob/ob mice and leptin-receptor-deficient db/db mice develop prostate enlargement and urethral changes that exacerbate voiding symptoms, while increased intra-abdominal pressure from visceral fat mechanically stresses the pelvic floor. In female Zucker fatty rats, impaired contractility of the circular striated urethral sphincter contributes to stress urinary incontinence, a finding that parallels clinical data from weight-loss trials showing symptom improvement after bariatric intervention. Hormonal shifts add another layer: adipose tissue converts androgens to oestrogens, and the resulting altered oestrogen-to-testosterone ratio has been implicated in prostate inflammation and fibrosis in obese men and in corresponding animal models.

Dyslipidaemia and vascular disease supply a third mechanism: chronic ischaemia. Apolipoprotein E knockout mice, which develop systemic atherosclerosis, exhibit bladder remodelling and detrusor overactivity driven by reduced blood flow, oxidative stress and proinflammatory cytokines. Rabbit and rat models of atherosclerosis-induced bladder ischaemia show fibrosis and loss of compliance, and high-fat diets have been shown to decrease mitochondrial respiration in detrusor muscle while increasing nerve-mediated contractions. A growing body of work also implicates succinate, a metabolite that accumulates in metabolic syndrome, as a signalling molecule that directly impairs bladder function through its receptor SUCNR1, offering a concrete biochemical link between disordered metabolism and urinary symptoms.

Hypertension, the fourth pillar of metabolic syndrome, acts largely through the renin-angiotensin system. Spontaneously hypertensive rats and Dahl salt-sensitive rats develop storage dysfunction and, with aging, detrusor underactivity, accompanied by reduced bladder blood flow and elevated oxidative stress. Angiotensin II type 1 receptor blockers such as olmesartan and losartan improve urinary function in these animals by restoring perfusion and reducing oxidative damage, findings consistent with clinical observations that hypertensive patients treated with angiotensin receptor blockers report fewer lower urinary tract symptoms. Circadian disruption of bladder clock genes in hypertensive rats may further explain nocturia, one of the most bothersome symptoms in metabolic patients.

The review also highlights less obvious contributors. Early-life stress models show that adverse experiences in youth promote visceral adiposity and bladder hypersensitivity in adulthood, connecting psychological stress, obesity and urinary dysfunction through shared neuroendocrine pathways. Sex differences emerge repeatedly: urodynamic studies in rhesus macaques reveal sexual dimorphism in detrusor function, and aged primates with metabolic syndrome develop detrusor underactivity, providing a translational bridge that rodent studies cannot always offer. Notably, no single animal model reproduces the complete human metabolic syndrome phenotype, a limitation the authors emphasize throughout.

Methodological caveats also temper enthusiasm. Standard urodynamic testing in rodents uses non-physiologically rapid bladder filling rates, which can exaggerate afferent signalling and distort storage phenotypes, and interspecies differences in bladder anatomy, innervation and metabolism complicate extrapolation to humans. Substrain differences in response to high-fat diets further muddy comparisons between laboratories. These constraints help explain why promising preclinical findings have not always translated into effective treatments for metabolic bladder dysfunction.

The path forward, the authors argue, lies in integration. Multi-omics approaches applied to model tissues are already identifying dysregulated protein subnetworks and metabolic signatures in the diabetic bladder, while human pluripotent stem cell-derived urothelial organoids and patient-derived urinoids offer platforms for validating mechanisms and testing biomarkers without species barriers. Combining longitudinal monitoring in animal models with human-relevant in vitro systems could enable personalized therapies tailored to a patient’s specific metabolic profile, though ethical challenges surrounding clinical translation remain. For a condition that erodes quality of life on a massive scale, the humble laboratory mouse and its successors may finally be pointing the way to treatments that address the metabolic roots of urinary dysfunction rather than merely its symptoms.

Subject of Research: Preclinical animal models of metabolic syndrome-associated lower urinary tract dysfunction

Article Title: Preclinical animal models of lower urinary tract dysfunction associated with metabolic syndrome

Article References: Covarrubias, C., Sirmakesyan, S., Hamouda, A., Lasri, S., AlAmeeri, A., Saint-Vil, D.-L., Cammisotto, P. G., & Campeau, L. (2026). Preclinical animal models of lower urinary tract dysfunction associated with metabolic syndrome. Nature Reviews Urology. https://doi.org/10.1038/s41585-026-01188-x

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01188-x

Keywords: metabolic syndrome, lower urinary tract dysfunction, diabetic bladder dysfunction, obesity, animal models, bladder ischaemia, hypertension, dyslipidaemia, urodynamics, organoids, insulin resistance, detrusor